​

AN2 Therapeutics Stock (NASDAQ:ANTX)

ForecastOwnershipFinancialsChart
AN2 Therapeutics by TradingView

Previous Close

$4.92

52W Range

$1.00 - $6.91

50D Avg

$4.63

200D Avg

$2.71

Market Cap

$177.20M

Avg Vol (3M)

$298.64K

Beta

-0.99

Div Yield

$2.63

ANTX Company Profile

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

21

IPO Date

Mar 25, 2022

Website

ANTX Performance

ANTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-38.11M$-54.55M$-69.64M
Net Income$-35.17M$-51.32M$-64.73M
EBITDA$-38.11M$3.23M$4.90M
Basic EPS$-1.16$-1.72$-2.74
Diluted EPS$-1.16$-1.72$-2.74

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PLURPluri Inc.
INTSIntensity Therapeutics, Inc.
IBIOiBio, Inc.
NXTCNextCure, Inc.
QTTBQ32 Bio Inc.
VRCAVerrica Pharmaceuticals Inc.
SABSSAB Biotherapeutics, Inc.
BOLDBoundless Bio, Inc.
PSTVPlus Therapeutics, Inc.